注射用头孢他啶使用说明书--达力啶

消炎片
【药品名称】
通用名称：消炎片
【成份】
蒲公英、紫花地丁、野菊花、黄芩。

辅料为：淀粉、硬脂酸镁。

【功能主治】
清热解毒。

用于上呼吸道感染的发热；支气管炎的咳嗽有痰及疖肿。

【用法用量】
口服。

一次4-6片，一日3-4次。

【不良反应】
尚不明确。

【禁忌】
孕妇禁用。

【注意事项】
1. 忌烟、酒及辛辣、油腻食物。

2.服药期间要保持情绪乐观，切忌生气恼怒。

3.有高血压、心脏病、糖尿病、肝病、肾病等慢性病严重者应在医生指导下服用。

4.服药7天症状无缓解，应去医院就诊。

5.儿童、孕妇、年老体弱者应在医生指导下服用。

6.对本品过敏者禁用，过敏体质都慎用。

7.药品性状发生改变时禁止服用。

8.儿童必须在成人监护下使用。

9.请将此药品放在儿童不能接触的地方。

10.如正在服用其他药品，使用本品前请咨询医师或药师
【特殊人群用药】
妊娠与哺乳期注意事项：
孕妇禁用。

【药物相互作用】
如与其他药物同时使用可能会发生药物相互作用，详情请咨询医师或药师。

【贮藏】
密封
【有效期】
36个月
【批准文号】
国药准字Z22025041
【生产企业】
企业名称：修正药业集团股份有限公司
生产地址：吉林省通化市修正路36号。

注射用头孢他啶阿维巴坦钠CAZ-AVI商品名：思福妥英文名：Ceftazidime and Avibactam Sodium for Injection汉语拼音：Zhu She Yong Tou Bao Ta Ding A Wei Ba Tan Na【成份】本品为复方制剂，其组分为头孢他啶五水合物（相当于头孢他啶C22H22N6O7S2 2.0g）和阿维巴坦钠（相当于阿维巴坦C7H11N3O6S 0.5g）。

头孢他啶五水合物：化学名称：(6R,7R)-7-[[(2-氨基-4-噻唑基)-[(1-羧基-1-甲基乙氧基)亚氨基]乙酰基]氨基]-2-羧基-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-3-甲基吡啶鎓内盐五水合物。

化学结构式：分子式：C22H32N6O12S2分子量：636.7阿维巴坦钠：化学名称：[(2S,5R)-2-氨基甲酰基-7-氧代-1,6-二氮杂双环[3.2.1]-辛烷-6-基]硫酸钠。

化学结构式：分子式：C7H10N3O6SNa分子量：287.23辅料：无水碳酸钠。

【性状】本品为白色至淡黄色粉末。

【适应症】1、复杂性腹腔内感染（cIAI）：本品适用于联合甲硝唑治疗18岁及以上患者中由下列对本品敏感的革兰阴性菌引起的复杂性腹腔内感染：大肠埃希菌、肺炎克雷伯菌、奇异变形杆菌、阴沟肠杆菌、产酸克雷伯菌、弗氏柠檬酸杆菌复合体和铜绿假单胞菌。

2、医院获得性肺炎和呼吸机相关性肺炎（HAP/VAP）：本品适用于治疗18岁及以上患者中由下列对本品敏感的革兰阴性菌引起的医院获得性肺炎和呼吸机相关性肺炎：肺炎克雷伯菌、阴沟肠杆菌、大肠埃希菌、粘质沙雷菌、奇异变形杆菌、铜绿假单胞菌和流感嗜血杆菌。

3、在治疗方案选择有限的成人患者中治疗由下列对本品敏感的革兰阴性菌引起的感染：肺炎克雷伯菌、阴沟肠杆菌、大肠埃希菌、奇异变形杆菌和铜绿假单胞菌。

本适应症是基于头孢他啶单独用药的经验以及对头孢他啶/阿维巴坦的药代动力学-药效学关系的分析。

注射用头孢西丁钠说明书【药品名称】通用名：注射用头孢西丁钠英文名：Cefoxitin Sodium for Injection汉语拼音：Zhusheyong Toubaoxidingna商品名：达力叮【成份】本品主要成份为头孢西丁钠，无辅料。

化学名称:(6R，7S)-3-[(1-氨甲酰氧)甲基]-7-甲氧基-8-氧代-7-[2-(2-噻吩基)乙酰氨基]-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-甲酸钠盐。

化学结构式：分子式：C16H16N3NaO7S2分子量：449.43Cas No：33564-30-6【性状】本品为白色或类白色粉末。

【适应症】适用于对本品敏感的细菌引起的下列感染:●上下呼吸道感染●泌尿道感染包括无并发症的淋病●腹膜炎以及其它腹腔内、盆腔内感染●败血症(包括伤寒)●妇科感染●骨、关节软组织感染●心内膜炎由于本品对厌氧菌有效及对β－内酰胺酶稳定，故特别适用需氧及厌氧菌混合感染，以及对于由产β－内酰胺酶而对本品敏感细菌引起的感染。

【规格】按C16H17N3O7S2 1.0g【用法用量】肌内注射、静注或静脉滴注。

成人常用量为1～2g/次，每6～8小时一次。

或根据致病菌的感染类型每日总剂量用法单纯性感染(肺炎、泌尿系统感染、皮肤感染) 3～4g 每6－8小时1g，肌注或静滴中、重度感染6～8g 每4小时1g或6－8小时2g静滴需大剂量抗生素治疗的感染(例如气性坏疽) 12g 每4小时2g或6小时3g静滴肾功能不全者则需按肌酐清除率调整剂量，按下表进行:3月以内婴儿不宜使用；3月以上儿童每次13.3～26.7mg/kg，每6小时1次或每次20mg～40mg/kg，每8小时1次。

围生期预防感染，剖腹产：脐带夹住时2g静注，4小时和8小时后各追加一次剂量；其他外科手术：术前1～1.5小时2g静注，以后24小时以内，每6小时用药1次，每次1g。

本品用于肌内注射，每克溶于0.5％盐酸利多卡因2ml；静注时，每克溶于10ml灭菌注射用水；静滴时，1～2g头孢西丁钠溶于50ml或100ml 0.9%氯化钠注射液或5％或10％葡萄糖注射液中。

头孢他啶用法用量是什么？有没有不良反应？头孢他啶是一种常见的抗生素，常用于治疗各种细菌感染。

正确的使用方法和用量对于疗效的发挥至关重要，同时也需要了解可能出现的不良反应，以便及时处理。

本文将介绍头孢他啶的用法用量及可能的不良反应。

用法用量头孢他啶可以以口服或静脉注射的方式使用，具体的用法用量如下：1.口服：–对于成人和儿童，通常建议每日分2-4次口服，每次剂量为250-500毫克，根据感染情况和医生的建议进行调整。

–严重感染时，剂量可能会增加，但不应超过每日4克。

–头孢他啶可用空腹或饭后服用，但应尽量保持规律服药，避免漏服。

2.静脉注射：–静脉注射头孢他啶通常用于严重感染或无法口服的情况下。

–剂量和给药频率应根据感染的类型和严重程度进行调整，建议在医护人员的指导下进行。

在使用头孢他啶时，应根据医生的建议严格遵循用药指导，不可自行增减剂量或中止用药。

不良反应虽然头孢他啶是一种常见的抗生素，但也存在一些不良反应，包括但不限于以下情况：1.消化系统反应：–可能出现恶心、呕吐、腹泻等消化不良症状。

–在用药过程中如果出现严重腹泻或胃肠道不适，应及时就医。

2.过敏反应：–个别患者对头孢他啶可能产生过敏反应，表现为皮疹、荨麻疹、药疹等。

–严重过敏反应可能引起呼吸困难、过敏性休克等危急情况，需立即就医处理。

3.其他不良反应：–头孢他啶还可能引起头晕、头痛、胃肠道不适、黄疸等不良反应，需密切观察病情并及时就医。

在使用头孢他啶期间，如出现任何不良反应或疑似过敏现象，应立即停止用药，并就医寻求帮助。

结语综上所述，头孢他啶是一种常用的抗生素药物，正确的使用方法和用量对于疗效的发挥至关重要。

同时，了解可能出现的不良反应并及时处理，可以减少并发症的发生，提高治疗效果。

在使用头孢他啶时，务必遵循医生的指导，严格按照药物说明书上的用药要求进行用药，并在必要时就医咨询。

1PRODUCT INFORMATIONCEPTAZ®2(ceftazidime for injection)3L-arginine formulation45For Intravenous or Intramuscular Use678DESCRIPTION: Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic forparenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-910carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-11en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure:12131415The empirical formula is C22H32N6O12S2, representing a molecular weight of 636.6.CEPTAZ is a sterile, dry mixture of ceftazidime pentahydrate and L-arginine. The L-arginine1617is at a concentration of 349 mg/g of ceftazidime activity. CEPTAZ dissolves without the18evolution of gas. The product contains no sodium ion. Solutions of CEPTAZ range in color from 19light yellow to amber, depending on the diluent and volume used. The pH of freshly constituted 20solutions usually ranges from 5 to 7.5.2122CLINICAL PHARMACOLOGY: After intravenous (IV) administration of 500-mg and 1-g doses of ceftazidime over 5 minutes to normal adult male volunteers, mean peak serum2324concentrations of 45 and 90 mcg/mL, respectively, were achieved. After IV infusion of 500-mg, 251-g, and 2-g doses of ceftazidime over 20 to 30 minutes to normal adult male volunteers, mean peak serum concentrations of 42, 69, and 170 mcg/mL, respectively, were achieved. The average2627serum concentrations following IV infusion of 500-mg, 1-g, and 2-g doses to these volunteers28over an 8-hour interval are given in Table 1.2930Table 1Ceftazidime Serum Concentrations (mcg/mL)IV Dose 0.5 h 1 h 2 h 4 h 8 hmg 42 25 12 6 2 500g 60 39 23 11 31g 129 75 42 13 523132The absorption and elimination of ceftazidime were directly proportional to the size of the33dose. The half-life following IV administration was approximately 1.9 hours. Less than 10% of 34ceftazidime was protein bound. The degree of protein binding was independent of concentration.There was no evidence of accumulation of ceftazidime in the serum in individuals with normal3536renal function following multiple IV doses of 1 and 2 g every 8 hours for 10 days.37Following intramuscular (IM) administration of 500-mg and 1-g doses of ceftazidime to38normal adult volunteers, the mean peak serum concentrations were 17 and 39 mcg/mL,39respectively, at approximately 1 hour. Serum concentrations remained above 4 mcg/mL for 6 and 408 hours after the IM administration of 500-mg and 1-g doses, respectively. The half-life of41ceftazidime in these volunteers was approximately 2 hours.42The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in 43individuals administered 2 g intravenously every 8 hours for 5 days. Therefore, a dosage44adjustment from the normal recommended dosage is not required for patients with hepatic45dysfunction, provided renal function is not impaired.46Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the 47kidneys over a 24-hour period. After the IV administration of single 500-mg or 1-g doses,approximately 50% of the dose appeared in the urine in the first 2 hours. An additional 20% was4849excreted between 2 and 4 hours after dosing, and approximately another 12% of the doseappeared in the urine between 4 and 8 hours later. The elimination of ceftazidime by the kidneys5051resulted in high therapeutic concentrations in the urine.52The mean renal clearance of ceftazidime was approximately 100 mL/min. The calculated53plasma clearance of approximately 115 mL/min indicated nearly complete elimination of54ceftazidime by the renal route. Administration of probenecid before dosing had no effect on the 55elimination kinetics of ceftazidime. This suggested that ceftazidime is eliminated by glomerular 56filtration and is not actively secreted by renal tubular mechanisms.57Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly 58prolonged in patients with impaired renal function. Consequently, dosage adjustments in such59patients as described in the DOSAGE AND ADMINISTRATION section are suggested.60Ceftazidime concentrations achieved in specific body tissues and fluids are depicted in61Table 2.62Table 2: Ceftazidime Concentrations in Body Tissues and Fluids 63Tissue or Fluid Dose/ RouteNo. ofPatientsTime ofSamplePostdoseAverage Tissueor Fluid Level(mcg/mL ormcg/g)Urine 500 mg IM 6 0-2 h 2,100.02 g IV 6 0-2 h 12,000.0Bile 2 g IV 3 90 min 36.4Synovial fluid 2 g IV 13 2 h 25.6Peritoneal fluid 2 g IV 8 2 h 48.6Sputum 1 g IV 8 1 h 9.0Cerebrospinal fluid 2 g q8h IV 5 120 min 9.8(inflamed meninges) 2 g q8h IV 6 180 min 9.4Aqueous humor 2 g IV 13 1-3 h 11.0Blister fluid 1 g IV 7 2-3 h 19.7Lymphatic fluid 1 g IV 7 2-3 h 23.4Bone 2 g IV 8 0.67 h 31.1Heart muscle 2 g IV 35 30-280 min 12.7Skin 2 g IV 22 30-180 min 6.6Skeletal muscle 2 g IV 35 30-280 min 9.4Myometrium 2 g IV 31 1-2 h 18.764Microbiology: Ceftazidime is bactericidal in action, exerting its effect by inhibition of enzymes 65responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to66ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In67addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly 68stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced 69by both gram-negative and gram-positive organisms and, consequently, is active against many 70strains resistant to ampicillin and other cephalosporins.71Ceftazidime has been shown to be active against the following organisms both in vitro and in 72clinical infections (see INDICATIONS AND USAGE).7374Aerobes,Gram-negative:Citrobacter spp., including Citrobacter freundii and Citrobacter75diversus; Enterobacter spp., including Enterobacter cloacae and Enterobacter aerogenes;76Escherichia coli; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.77(including Klebsiella pneumoniae); Neisseria meningitidis; Proteus mirabilis; Proteus vulgaris;78Pseudomonas spp. (including Pseudomonas aeruginosa); and Serratia spp.79Aerobes, Gram-positive:Staphylococcus aureus, including penicillinase- and non–80penicillinase-producing strains; Streptococcus agalactiae (group B streptococci); Streptococcus 81pneumoniae; and Streptococcus pyogenes (group A beta-hemolytic streptococci).Anaerobes:Bacteroides spp. (NOTE: many strains of Bacteroides fragilis are resistant).8283Ceftazidime has been shown to be active in vitro against most strains of the following organisms; however, the clinical significance of this activity is unknown: Acinetobacter spp.,8485Clostridium spp. (not including Clostridium difficile), Haemophilus parainfluenzae, Morganella 86morganii (formerly Proteus morganii), Neisseria gonorrhoeae, Peptococcus spp.,87Peptostreptococcus spp., Providencia spp. (including Providencia rettgeri, formerly Proteus88rettgeri), Salmonella spp., Shigella spp., Staphylococcus epidermidis, and Yersinia89enterocolitica.Ceftazidime and the aminoglycosides have been shown to be synergistic in vitro against9091Pseudomonas aeruginosa and the enterobacteriaceae. Ceftazidime and carbenicillin have also 92been shown to be synergistic in vitro against Pseudomonas aeruginosa.93Ceftazidime is not active in vitro against methicillin-resistant staphylococci, Streptococcus94faecalis and many other enterococci, Listeria monocytogenes, Campylobacter spp., or95Clostridium difficile.96Susceptibility Tests:Diffusion Techniques:Quantitative methods that require measurement of 97zone diameters give an estimate of antibiotic susceptibility. One such procedure1-3 has been98recommended for use with disks to test susceptibility to ceftazidime.99Reports from the laboratory giving results of the standard single-disk susceptibility test with a 30-mcg ceftazidime disk should be interpreted according to the following criteria:100101Susceptible organisms produce zones of 18 mm or greater, indicating that the test organism 102is likely to respond to therapy.Organisms that produce zones of 15 to 17 mm are expected to be susceptible if high dosage 103104is used or if the infection is confined to tissues and fluids (e.g., urine) in which high antibiotic 105levels are attained.106Resistant organisms produce zones of 14 mm or less, indicating that other therapy should be 107selected.108Organisms should be tested with the ceftazidime disk since ceftazidime has been shown by in 109vitro tests to be active against certain strains found resistant when other beta-lactam disks are 110used.111Standardized procedures require the use of laboratory control organisms. The 30-mcg ceftazidime disk should give zone diameters between 25 and 32 mm for Escherichia coli112113ATCC 25922. For Pseudomonas aeruginosa ATCC 27853, the zone diameters should bebetween 22 and 29 mm. For Staphylococcus aureus ATCC 25923, the zone diameters should be 114115between 16 and 20 mm.116Dilution Techniques:In other susceptibility testing procedures, e.g., ICS agar dilution or the 117equivalent, a bacterial isolate may be considered susceptible if the minimum inhibitory118concentration (MIC) value for ceftazidime is not more than 16 mcg/mL. Organisms are119considered resistant to ceftazidime if the MIC is ≥64 mcg/mL. Organisms having an MIC value 120of <64 mcg/mL but >16 mcg/mL are expected to be susceptible if high dosage is used or if the 121infection is confined to tissues and fluids (e.g., urine) in which high antibiotic levels are attained. 122As with standard diffusion methods, dilution procedures require the use of laboratory control 123organisms. Standard ceftazidime powder should give MIC values in the range of 4 to 16 mcg/mL 124for Staphylococcus aureus ATCC 25923. For Escherichia coli ATCC 25922, the MIC range125should be between 0.125 and 0.5 mcg/mL. For Pseudomonas aeruginosa ATCC 27853, the MIC 126range should be between 0.5 and 2 mcg/mL.127128INDICATIONS AND USAGE: CEPTAZ is indicated for the treatment of patients with129infections caused by susceptible strains of the designated organisms in the following diseases: 1301.Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas131aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including132ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichiacoli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus 133134(methicillin-susceptible strains).1352.Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; 136Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus;137Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and 138Streptococcus pyogenes (group A beta-hemolytic streptococci).1393. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas140aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive 141Proteus; Klebsiella spp.; and Escherichia coli.4.Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus142143influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcusaureus (methicillin-susceptible strains).1441455. Bone and Joint Infections caused by Pseudomonas aeruginosa,Klebsiella spp., Enterobacter 146spp., and Staphylococcus aureus (methicillin-susceptible strains).1476.Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the 148female genital tract caused by Escherichia coli.1497.Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp.,and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections150151caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides 152fragilis are resistant).1538.Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae 154and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of 155cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae.156Specimens for bacterial cultures should be obtained before therapy in order to isolate and157identify causative organisms and to determine their susceptibility to ceftazidime. Therapy may be 158instituted before results of susceptibility studies are known; however, once these results become 159available, the antibiotic treatment should be adjusted accordingly.CEPTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been 160161used successfully in clinical trials as empiric therapy in cases where various concomitant162therapies with other antibiotics have been used.163CEPTAZ may also be used concomitantly with other antibiotics, such as aminoglycosides, 164vancomycin, and clindamycin; in severe and life-threatening infections; and in the165immunocompromised patient (see COMPATIBILITY AND STABILITY). When such166concomitant treatment is appropriate, prescribing information in the labeling for the otherantibiotics should be followed. The dosage depends on the severity of the infection and the167168patient's condition.169170CONTRAINDICATIONS: CEPTAZ is contraindicated in patients who have shown171hypersensitivity to ceftazidime or the cephalosporin group of antibiotics.172173WARNINGS: BEFORE THERAPY WITH CEPTAZ IS INSTITUTED, CAREFUL INQUIRY 174SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS 175HYPERSENSITIVITY REACTIONS TO CEFTAZIDIME, CEPHALOSPORINS,176PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TOPENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE 177178CROSS-HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEENCLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A 179180HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEPTAZ181OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY182REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER183EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, 184CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS185CLINICALLY INDICATED.186Pseudomembranous colitis has been reported with nearly all antibacterial agents,187including ceftazidime, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to 188189the administration of antibacterial agents.Treatment with antibacterial agents alters the normal flora of the colon and may permit190191overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one 192primary cause of "antibiotic-associated colitis."After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic 193194measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug195discontinuation alone. In moderate to severe cases, consideration should be given to management196with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug197clinically effective against Clostridium difficile colitis.198Elevated levels of ceftazidime in patients with renal insufficiency can lead to seizures,encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia (see199200PRECAUTIONS).201202PRECAUTIONS:203General: High and prolonged serum ceftazidime concentrations can occur from usual dosages in204patients with transient or persistent reduction of urinary output because of renal insufficiency.205The total daily dosage should be reduced when ceftazidime is administered to patients with renal206insufficiency (see DOSAGE AND ADMINISTRATION). Elevated levels of ceftazidime in thesepatients can lead to seizures, encephalopathy, coma, asterixis, neuromuscular excitability, and 207208myoclonia. Continued dosage should be determined by degree of renal impairment, severity ofinfection, and susceptibility of the causative organisms.209210As with other antibiotics, prolonged use of CEPTAZ may result in overgrowth of211nonsusceptible organisms. Repeated evaluation of the patient's condition is essential. If212superinfection occurs during therapy, appropriate measures should be taken.213Inducible type I beta-lactamase resistance has been noted with some organisms (e.g.,214Enterobacter spp.,Pseudomonas spp., and Serratia spp.). As with other extended-spectrum215beta-lactam antibiotics, resistance can develop during therapy, leading to clinical failure in some216cases. When treating infections caused by these organisms, periodic susceptibility testing should217be performed when clinically appropriate. If patients fail to respond to monotherapy, anaminoglycoside or similar agent should be considered.218219Cephalosporins may be associated with a fall in prothrombin activity. Those at risk includepatients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a 220221protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at222risk and exogenous vitamin K administered as indicated.CEPTAZ should be prescribed with caution in individuals with a history of gastrointestinal 223224disease, particularly colitis.225Arginine has been shown to alter glucose metabolism and elevate serum potassium transiently 226when administered at 50 times the recommended dose. The effect of lower dosing is not known. 227Distal necrosis can occur after inadvertent intra-arterial administration of ceftazidime.228Drug Interactions: Nephrotoxicity has been reported following concomitant administration of 229cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide. Renal 230function should be carefully monitored, especially if higher dosages of the aminoglycosides are to 231be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics. Nephrotoxicity and ototoxicity were not noted when ceftazidime 232233was given alone in clinical trials.Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including234235ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli. Due 236to the possibility of antagonism in vivo, particularly when bactericidal activity is desired, this 237drug combination should be avoided.238Drug/Laboratory Test Interactions: The administration of ceftazidime may result in a239false-positive reaction for glucose in the urine when using CLINITEST® tablets, Benedict'ssolution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose 240241oxidase reactions (such as CLINISTIX®) be used.242Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not 243been performed to evaluate carcinogenic potential. However, a mouse Micronucleus test and an 244Ames test were both negative for mutagenic effects.245Pregnancy:Teratogenic Effects: Pregnancy Category B. Reproduction studies have been246performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence 247of impaired fertility or harm to the fetus due to ceftazidime. CEPTAZ at 23 times the human dose 248was not teratogenic or embryotoxic in a rat reproduction study. There are, however, no adequate 249and well-controlled studies in pregnant women. Because animal reproduction studies are notalways predictive of human response, this drug should be used during pregnancy only if clearly 250251needed.252Nursing Mothers: Ceftazidime is excreted in human milk in low concentrations. It is not knownwhether the arginine component of this product is excreted in human milk. Because many drugs 253254are excreted in human milk and because safety of the arginine component of CEPTAZ in nursing 255infants has not been established, a decision should be made whether to discontinue nursing or to 256discontinue the drug, taking into account the importance of the drug to the mother.257Pediatric Use: Safety of the arginine component of CEPTAZ in neonates, infants, and children 258has not been established. This product is for use in patients 12 years and older. If treatment with ceftazidime is indicated for neonates, infants, or children, a sodium carbonate formulation should 259260be used.261262ADVERSE REACTIONS: The following adverse effects from clinical trials were considered to 263be either related to ceftazidime therapy or were of uncertain etiology. The most common were 264local reactions following IV injection and allergic and gastrointestinal reactions. No265disulfiramlike reactions were reported.266Local Effects, reported in fewer than 2% of patients, were phlebitis and inflammation at the site of injection (1 in 69 patients).267268Hypersensitivity Reactions, reported in 2% of patients, were pruritus, rash, and fever.Immediate reactions, generally manifested by rash and/or pruritus, occurred in 1 in 285 patients. 269270Toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have also been 271reported with cephalosporin antibiotics, including ceftazidime. Angioedema and anaphylaxis 272(bronchospasm and/or hypotension) have been reported very rarely.273Gastrointestinal Symptoms, reported in fewer than 2% of patients, were diarrhea (1 in 78),274nausea (1 in 156), vomiting (1 in 500), and abdominal pain (1 in 416). The onset of275pseudomembranous colitis symptoms may occur during or after treatment (see WARNINGS). 276Central Nervous System Reactions (fewer than 1%) included headache, dizziness, and277paresthesia. Seizures have been reported with several cephalosporins, including ceftazidime. In addition, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been 278279reported in renally impaired patients treated with unadjusted dosage regimens of ceftazidime (see PRECAUTIONS: General).280281Less Frequent Adverse Events (fewer than 1%) were candidiasis (including oral thrush) and 282vaginitis.Hematologic: Rare cases of hemolytic anemia have been reported.283284Laboratory Test Changes noted during ceftazidime clinical trials were transient and included: 285eosinophilia (1 in 13), positive Coombs' test without hemolysis (1 in 23), thrombocytosis (1 in 28645), and slight elevations in one or more of the hepatic enzymes, aspartate aminotransferase287(AST, SGOT) (1 in 16), alanine aminotransferase (ALT, SGPT) (1 in 15), LDH (1 in 18), GGT (1 288in 19), and alkaline phosphatase (1 in 23). As with some other cephalosporins, transient289elevations of blood urea, blood urea nitrogen, and/or serum creatinine were observed290occasionally. Transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia, and291lymphocytosis were seen very rarely.292293POSTMARKETING EXPERIENCE WITH CEPTAZ PRODUCTS: In addition to theadverse events reported during clinical trials, the following events have been observed during 294295clinical practice in patients treated with CEPTAZ and were reported spontaneously. For some of 296these events, data are insufficient to allow an estimate of incidence or to establish causation.297General: Anaphylaxis; allergic reactions, which, in rare instances, were severe (e.g.,298cardiopulmonary arrest); urticaria; pain at injection site.299Hepatobiliary Tract: Hyperbilirubinemia, jaundice.300Renal and Genitourinary: Renal impairment.301Cephalosporin-Class Adverse Reactions: In addition to the adverse reactions listed above that 302have been observed in patients treated with ceftazidime, the following adverse reactions and303altered laboratory tests have been reported for cephalosporin-class antibiotics:304Adverse Reactions:Colitis, toxic nephropathy, hepatic dysfunction including cholestasis, 305aplastic anemia, hemorrhage.306Altered Laboratory Tests:Prolonged prothrombin time, false-positive test for urinary307glucose, pancytopenia.308309OVERDOSAGE: Ceftazidime overdosage has occurred in patients with renal failure. Reactions 310have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma. 311Patients who receive an acute overdosage should be carefully observed and given supportive312treatment. In the presence of renal insufficiency, hemodialysis or peritoneal dialysis may aid inthe removal of ceftazidime from the body.313314315DOSAGE AND ADMINISTRATION:Dosage: The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 316317to 12 hours. The dosage and route should be determined by the susceptibility of the causative 318organisms, the severity of infection, and the condition and renal function of the patient.319The guidelines for dosage of CEPTAZ are listed in Table 3. The following dosage schedule is 320recommended.321Table 3: Recommended Dosage Schedule322DoseFrequency Patients 12 years and older*Usual recommended dosage 1 gram IV or IM q8-12hUncomplicated urinary tract infections 250 mg IV or IM q12hBone and joint infections 2 grams IV q12hComplicated urinary tract infections 500 mg IV or IM q8-12hUncomplicated pneumonia; mild skin and skin- structure infections 500 mg-1 gramIV or IM q8hSerious gynecologic and intra-abdominal infections 2 grams IV q8h Meningitis 2 grams IV q8h Very severe life-threatening infections, especiallyin immunocompromised patients 2 grams IV q8hLung infections caused by Pseudomonas spp. in patients with cystic fibrosis with normal renal function†30-50 mg/kg IVto a maximumof 6 grams per day q8h* This product is for use in patients 12 years and older. If treatment with ceftazidime is323indicated for patients less than 12 years old, a sodium carbonate formulation should324be used.325†Although clinical improvement has been shown, bacteriologic cures cannot be326expected in patients with chronic respiratory disease and cystic fibrosis.327328Impaired Hepatic Function: No adjustment in dosage is required for patients with hepatic 329dysfunction.330Impaired Renal Function: Ceftazidime is excreted by the kidneys, almost exclusively by 331glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration 332rate [GFR]<50 mL/min), it is recommended that the dosage of ceftazidime be reduced to333compensate for its slower excretion. In patients with suspected renal insufficiency, an initial334loading dose of 1 gram of CEPTAZ may be given. An estimate of GFR should be made to335determine the appropriate maintenance dosage. The recommended dosage is presented in Table 4. 336。

注射用头孢他啶Ceftazidime for Injection【成份】本品主要成份为头孢他啶，化学名称为：(6R ，7R)-7-[[(2-氨基-4-噻唑基)-[(1-羧基-1-甲基乙氧基)亚氨基]乙酰基]氨基]-2-羧基-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-3-甲基吡啶鎓内盐五水合物。

化学结构式：分子式：C22H22N6O7S2•5H2O分子量：636.65辅料名称：碳酸钠【性状】本品为白色或类白色结晶性粉末。

【适应症】用于敏感革兰氏阴性杆菌所致的败血症、下呼吸道感染、腹腔和胆道感染、复杂性尿路感染和严重皮肤软组织感染等。

对于由多种耐药革兰氏阴性杆菌引起的免疫缺陷者感染、医院内感染以及革兰氏阴性杆菌或铜绿假单胞菌所致中枢神经系统感染尤为适用。

【规格】按C22H22N6O7S2计算1.0g【用法用量】静脉注射或静脉滴注。

1．败血症、下呼吸道感染、胆道感染等，一日4～6g，分2～3次静脉滴注或静脉注射，疗程10～14日。

2．泌尿系统感染和重度皮肤软组织感染等，一日2～4g，分2次静脉滴注或静脉注射，疗程7～14日。

3．对于某些危及生命的感染、严重铜绿假单胞菌感染和中枢神经系统感染，可酌情增量至一日0.15～0.2g/kg，分3次静脉滴注或静脉注射。

4.婴幼儿常用剂量为一日30～100mg/kg，分2～3次静脉滴注。

【不良反应】本品的不良反应少见而轻微。

少数患者可发生皮疹、皮肤瘙痒、药物热；恶心、腹泻、腹痛；注射部位轻度静脉炎；偶可发生一过性血清氨基转移酶酶、血尿素氮、血肌酐值的轻度升高；白细胞、血小板减少及嗜酸性粒细胞增多等。

【禁忌】对头孢菌素类抗生素过敏者禁用。

【注意事项】1．交叉过敏反应：对一种头孢菌素或头霉素(cephamycin)过敏者对其他头孢菌素或头霉素也可能过敏。

对青霉素类、青霉素衍生物或青霉胺过敏者也可能对头孢菌素或头霉素过敏。

对青霉素过敏病人应用头孢菌素时发生过敏反应者达5%～10%；如作过敏试验，则对青霉素过敏病人对头孢菌素过敏者达20%。

临床头孢他啶药物常规用药、剂量调整、给药说明、贮藏、药物警戒、不良反应、禁忌症、注意事项、药物监控及药物过量常规用药头孢他啶是用于肠胃外给药的半合成、广谱、β-内酰胺类抗菌药物。

可用于敏感微生物引起的单一或多重感染。

成人常用剂量头孢他啶可用于治疗由敏感微生物引起的单一或多重感染，具体如下：◆全身性重度感染：由假单胞菌属（包括铜绿假单胞菌）、流感嗜血杆菌（包括氨苄西林耐药菌株）、克雷伯菌属（包括克雷伯菌）、肠杆菌属、变形杆菌属、大肠埃希菌、沙雷氏菌属、枸橼酸杆菌属、肺炎链球菌和金黄色葡萄球菌（甲氧西林敏感菌株）引起的全身性重度感染，例如：败血症、菌血症、腹膜炎、免疫抑制患者的感染和重症监护患者的感染（如烧伤感染）。

◆下呼吸道感染（包括肺炎）：由假单胞菌属（包括铜绿假单胞菌）、流感嗜血杆菌（包括氨苄西林耐药菌株）、克雷伯菌属（包括肺炎克雷伯菌）、肠杆菌属、奇异变形杆菌、大肠埃希菌、沙雷氏菌属、枸橼酸杆菌属、肺炎链球菌和金黄色葡萄球菌（甲氧西林敏感菌株）引起。

◆耳鼻喉感染：由假单胞菌属（包括铜绿假单胞菌）、流感嗜血杆菌（包括氨苄西林耐药菌株）、肺炎链球菌、金黄色葡萄球菌（甲氧西林敏感菌株）和酿脓链球菌（A 族β溶血性链球菌）引起。

◆尿路感染：由假单胞菌属（包括铜绿假单胞菌）、肠杆菌属、变形杆菌属（包括奇异变形杆菌和吲哚阳性变形杆菌）、克雷伯菌属和大肠埃希菌引起。

◆皮肤和软组织感染：由铜绿假单胞菌、克雷伯菌属、大肠埃希菌、变形杆菌属（包括奇异变形杆菌和吲哚阳性变形杆菌）、肠杆菌属、沙雷氏菌属、金黄色葡萄球菌（甲氧西林敏感菌株）和酿脓链球菌（A 族β溶血性链球菌）引起。

◆骨和关节感染：由铜绿假单胞菌、克雷伯菌属、肠杆菌属和金黄色葡萄球菌（甲氧西林敏感菌株）引起。

◆妇科感染：包括子宫内膜炎、盆腔蜂窝组织炎和其他由大肠埃希菌引起的女性生殖道感染。

◆胃肠道、胆道和腹部感染：包括由大肠埃希菌、克雷伯菌属和金黄色葡萄球菌（甲氧西林敏感菌株）引起的腹膜炎，以及由需氧和厌氧微生物以及拟杆菌（注意：许多脆弱拟杆菌菌株具有耐药性）引起的多种微生物感染。